Our study has revealed a proinflammatory signature in MS-derived monocytes and their products, with marked alterations in the NF-κB and aryl hydrocarbon receptor (AhR) pathways, which upon reversion improve their tolerogenicity and facilitate the design of a more potent second-generation VitD3-tolDC therapy. The gene discussed is AHR; the disease is myeloid sarcoma.